RetroEMBRACE

Background

RetroEMBRACE, international multicenter retrospective cohort, N=731, locally advanced cervical cancer (FIGO IB2–IVA) treated with definitive EBRT ± chemotherapy followed by MRI-based image-guided adaptive brachytherapy (IGABT) per GEC-ESTRO; 12 institutions, 9 countries, enrolled 2008–2011.

Interventions and follow up

Treatment: Definitive EBRT ± concurrent chemotherapy followed by MRI-based IGABT (GEC-ESTRO)
Primary endpoint: Local control, pelvic control, disease-specific survival, late morbidity
mFollow up: Median 46 month

Results

3-yr local control: 91% (vs ~75–80% historical LDR)
3-yr pelvic control: 87%
3-yr cause-specific survival: 79%
3-yr OS: 74%
Grade 3–4 late morbidity: Bladder 4%, rectum 4%, bowel 5% at 3 yr

Adverse events

Grade 3–4 late GI: ~5% (rectovaginal fistula 1.7%, bowel obstruction 1.2%)
Grade 3–4 late GU: ~4% (bladder fistula 1.4%)
Treatment-related deaths: None attributed to brachytherapy

Conclusions

MRI-guided adaptive brachytherapy after EBRT±CCRT achieves excellent 3-yr local control (91%) with low late morbidity in locally advanced cervical cancer, reducing local failure by ~10–15% vs historical LDR and establishing IGABT as the new brachytherapy standard.

Key Limitations

Retrospective design without randomized comparator; comparisons to historical LDR cohorts with different selection/staging; institutional technique variation; selection bias (high-volume IGABT-expert centers); not all fractions delivered with MRI guidance.

Clinical Context

Largest evidence base for MRI-guided IGABT in cervical cancer; catalyzed global adoption of GEC-ESTRO brachytherapy contouring. IGABT is now standard of care for brachytherapy in locally advanced cervical cancer per ASCO/ESMO and GEC-ESTRO; the prospective EMBRACE II is validating outcomes in the modern era.

References